TARGETING NEW CANCER SOLUTIONS
No patient should be denied the cancer care they need simply because some options are in short supply or unavailable. Yet, all too often, this is what happens.
At the core of many oncology therapies are radioisotopes. However, increasingly limited supply inhibits patient outcomes and the development of new therapies.
Advancements with radioisotopes
Nusano is combining time-proven technology from universities and world-class research centers with our own breakthrough, patented particle acceleration technology. The result is the first significant advancement in medical radioisotope production in decades – a platform fitting the needs of today and designed for cancer-fighting radiopharmaceuticals of tomorrow.
Life Saving Benefits
Health care has used radioisotopes for decades. But, if supply does not keep up with demand, patients will lose out on the benefits of these lifesaving, proven tools.
a healthy tomorrow
Nusano’s patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. When it opens, our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.
Nusano is driven by an experienced team of scientists, engineers, and innovators, and guided by leaders with deep expertise in health care, business development and operations.
Chief Executive Officer
Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. Read more >>
Chief executive officer
Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. He brings extensive strategic and operational expertise to Nusano, including licensing, financing and acquisitions. As CEO, Chris is responsible for setting the company’s strategic direction and overseeing key priorities.
Prior to Nusano, Lowe served as Chief Financial Officer and Chief Operating Officer of Cortexyme, Inc., a biotech company focused on Alzheimer’s and neurodegenerative diseases. There, he led the company’s IPO in 2019, oversaw a cash injection via a PIPE (private investment in public equity) in 2020, and guided the company’s eventual acquisition by Novosteo. Lowe holds a bachelor’s degree in Business from California Polytechnic State University, and an MBA in Finance from St. Mary’s University.
HOWARD C. LEWIN, MD, FACC, FASNC
CO-FOUNDER & CHIEF PRODUCT DEVELOPMENT OFFICER
Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine. Read more >>
Howard C. Lewin, MD, FACC, FASNC
Chief Operations Officer
Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine at Cedar Sinai Medical Center. His broad experience includes time as an academic physician and as president of two nuclear medicine businesses. Dr. Lewin built a large nuclear cardiology practice with offices in several states, and a successful cardiac PET business providing state-of-the art cardiac imaging.
Dr. Lewin is widely recognized for his contributions to Nuclear Cardiology and serves as an officer of the American Society of Nuclear Cardiology, the Society of Nuclear Medicine Cardiovascular Council, the Intersocietal Accreditation Commission for Nuclear Medicine/PET, and the Certification Council for Cardiovascular Imaging. He brings with him rich relationships in the radioisotope production and distribution sectors.
GLENN B. ROSENTHAL, PH.D.
CO-FOUNDER & CHIEF TECHNOLOGY OFFICER
Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer.
Read more >>
Glenn B. Rosenthal, Ph.D. – Chief Technology Officer
Chief Technology Officer
Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer. He is an expert in accelerated particle physics, isotope target design, and radioisotope specification and production processes. While at UCLA, Dr. Rosenthal was the Principal Investigator for a number of successful projects sponsored by the NSF, DARPA, the DOE, Siemens Nuclear Power, and others.
Prior to Nusano, Dr. Rosenthal worked at Nonlinear Ion Dynamics (NID), a private company established to commercialize technology he developed and patented while at UCLA. At NID, Dr. Rosenthal was awarded a grant from the NIH to develop an isotope separation method he invented. Dr. Rosenthal is author of a number of technical publications and holds several patents.
CHIEF OPERATIONS OFFICER
Alexandre Gibim is an experienced executive whose career spans multiple business functions and geographies, including full P&L responsibility at some of the world’s largest pharmaceutical companies.
Read more >>
Chief operations officer
Alexandre Gibim is an experienced pharmaceutical executive. His career spans multiple business functions and geographies, including full P&L responsibility in the United States, China, Canada, and Brazil at some of the world’s largest pharmaceutical companies. In these roles he led successful business transformation initiatives, created go-to-market strategies, built professional account management programs, and managed acquisition and divestment activities. He has a proven track record of leading teams with more than 2,000 people and has driven significant revenue growth in excess of USD $1 billion.
Most recently, Gibim was Senior VP, Head of North America, at Advanced Accelerator Applications, a Novartis company, where he orchestrated the successful U.S. launch of 177Lu-PSMA-617 (marketed as Pluvicto™), an innovative radiopharmaceutical for prostate cancer. This pioneering treatment has achieved widespread adoption and is significantly enhancing the lives of patients through transformative outcomes.
Board of Directors
Managing Partner, Section 32
Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology.
Andrew Conrad, PhD, is the Chief Executive Officer, Chairman and Founder of Verily.
Scott has over twenty years’ experience in the field of molecular imaging and therapeutics.
CEO, Section 32
Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.
Managing Director, Wasatch Equity Partners
Aaron is managing partner at Wasatch Equity Partners, an investment firm with more than $4 billion assets under management.
Chris Lowe (CEO) and Howard Lewin (CPDO), also serve on the Board of Directors.
DISCOVER MORE ABOUT NUSANO
Sign up to receive company news and updates